Key result
Premedication with intravenous midazolam (0.025 mg/kg) significantly reduced maternal anxiety scores compared to saline, without causing adverse effects on newborns.
Why the study?
Does midazolam premedication reduce maternal anxiety without causing neonatal adverse effects in obstetric patients scheduled for elective Caesarian section?
RCT
Does midazolam premedication reduce maternal anxiety without causing neonatal adverse effects in obstetric patients scheduled for elective Caesarian section?
Low-dose intravenous midazolam safely reduces maternal anxiety prior to elective Caesarean section without causing neonatal depression.
Low-dose midazolam may reduce maternal anxiety before elective cesarean without neonatal harm; leaves open confirmation in randomized trials.
Like all surgical patients, obstetric patients also feel operative stress and anxiety. This can be prevented by giving patients detailed information about their operation and with preoperative pharmacological medications. Because of depressive effects of sedatives on newborns, pharmacological medications are omitted, especially in obstetric patients. The literature contains few studies concerning preoperative midazolam use in Caesarian section (C/S) patients. Our aim in this study was to help patients undergoing C/S surgery. One group scheduled for elective C/S received midazolam 0.025 mg kg(-1) intravenously, the other received saline. Maternal anxiety was evaluated using Amsterdam Preoperative Anxiety and Information Scale (APAIS) scores, and newborns were evaluated using Apgar and the Neonatal Neurologic and Adaptive Capacity Score (NACS). In conclusion, patients receiving midazolam 0.025 mg kg(-1) as premedication had significantly low anxiety scores, without any adverse effects on the newborns. Midazolam can therefore safely be used as a premedicative agent in C/S surgery.
No takes yet. Share an insight, caveat, or question.
Şenel et al. (2013) conducted an RCT in Elective Caesarean section. Midazolam vs. Saline was evaluated on Maternal anxiety (APAIS scores) and neonatal adverse effects (Apgar and NACS scores). Premedication with intravenous midazolam (0.025 mg/kg) significantly reduced maternal anxiety scores compared to saline, without causing adverse effects on newborns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: